II. Indication
- Genital Wart
- Recalcitrant Common Warts (not FDA approved)
- Molluscum Contagiosum (not FDA approved)
III. Contraindications
- Do not use on mucous membranes
IV. Precautions
- Weakens Condoms and diaphragms
- Avoid sexual contact when cream is on skin
V. Dosing
-
General
- Apply thin layer to external visible lesions
- Rub in cream until it disappears
- Wash off with soap and water in 6-10 hours
-
Genital Warts
- Apply 5% cream to affected area qhs for 3 nights/week
- Apply at bedtime and wash off in 6-10 hours
- May repeat weekly cycles for up to 16 weeks
- Recalcitrant warts
- Apply 3 times per week for a maximum of 16 weeks
- Apparently very effective if extensive involvement
- Molloscum contagiosum
- Apply to skin lesion for 6-10 hours, then wash off
- Apply 3 times weekly for 4 to 16 weeks
VI. References
Images: Related links to external sites (from Bing)
Related Studies
imiquimod (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
IMIQUIMOD 5% CREAM PACKET | Generic | $0.96 each |
Ontology: imiquimod (C0165032)
Definition (NCI_NCI-GLOSS) | A drug used to treat early basal cell skin cancer and certain other skin conditions. It is being studied in the treatment of other types of cancer. Imiquimod is a type of biological response modifier. |
Definition (NCI) | A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. (NCI04) |
Definition (PDQ) | A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38558&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38558&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1431" NCI Thesaurus) |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C056493 |
SnomedCT | 108939005, 386941002 |
English | 1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine, 1H-Imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)-, imiquimod, 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline, IMQ, imiquimod (medication), wart therapeutic agents imiquimod, imiquimod [Chemical/Ingredient], IMIQUIMOD, Imiquimod, Imiquimod (product), Imiquimod (substance) |
Spanish | imiquimod (producto), imiquimod (sustancia), imiquimod |
Ontology: Aldara (C0718327)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C056493 |
English | aldara, 3M Brand of Imiquimod, Aldara |